Michael Joseph McCormack Jr., MD ...

Dr. Michael McCormack

Claim this profile

Wake Forest University Health Sciences

Studies Prostate Cancer
Studies Colon Cancer
16 reported clinical trials
47 drugs studied

Area of expertise

1

Prostate Cancer

Michael McCormack has run 5 trials for Prostate Cancer. Some of their research focus areas include:

Stage IV
2

Colon Cancer

Michael McCormack has run 2 trials for Colon Cancer. Some of their research focus areas include:

Stage II
Stage III
MSS positive

Affiliated Hospitals

Image of trial facility.

Wake Forest University Health Sciences

Image of trial facility.

Wake Forest University At Clemmons

Clinical Trials Michael McCormack is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Radioactive Drug Therapy

for Prostate Cancer

This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.

Recruiting

1 award

Phase 2

16 criteria

More about Michael McCormack

Clinical Trial Related

3 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical Trials

Treatments Michael McCormack has experience with

  • Oxaliplatin
  • Fluorouracil
  • Leucovorin Calcium
  • Durvalumab
  • MFOLFIRINOX
  • Nivolumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Michael McCormack specialize in?

Is Michael McCormack currently recruiting for clinical trials?

Are there any treatments that Michael McCormack has studied deeply?

What is the best way to schedule an appointment with Michael McCormack?

What is the office address of Michael McCormack?

Is there any support for travel costs?